Pfizer's Growth Story Faces a Wait as Pipeline and Leadership Doubts Mount

HSBC downgraded Pfizer (PFE), saying near-term “re-rating” prospects have weakened even as the stock’s dividend yield and long-term oncology ambitions remain attractive. The action is a cautious signal on near-term outlook rather than an immediate impairment of fundamentals.

Analysis

HSBC downgraded Pfizer (PFE), saying near-term “re-rating” prospects have weakened even as the stock’s dividend yield and long-term oncology ambitions remain attractive. The action is a cautious signal on near-term outlook rather than an immediate impairment of fundamentals.